BACKGROUND: Disseminated CASE SUMMARY: We present a case of a 45-year-old female breast cancer patient who developed DISCUSSION: The use of ICIs and the subsequent treatment of irAEs with immunosuppressants introduce a new subset of immunocompromised patients at risk for fungal infections. While alternative corticosteroid-sparing immune-modulating agents such as biologicals, intravenous immunoglobulins, and disease-modifying anti-rheumatic drugs have been explored, there is lack of prospective studies evaluating their efficacy and safety in this context.